CyberKnife
CyberKnife for lung cancer
Lung tumors move as a patient breathes. Explanation of target tracking, the context of lung SBRT, and what determines case review.
This information is not a diagnosis or a medical recommendation. Decisions remain with your medical team.
Lung tumors can move as a patient breathes
The question is simple: if the target moves whenever a patient breathes, how can radiation remain directed at the same point? The answer involves both the beam angles defined in the plan and position verification during the treatment session.
The following two steps come directly from this cluster's stereotactic-treatment workflow. TanyaKanker presents them as concepts, not as machine specifications.
Step 5
Robotic irradiation
Radiation is delivered from many angles toward the target.
Step 6
Tracking and correction
Target position is checked during the session and corrected if it shifts.
What is assessed: Motion and breathing
Where tracking fits into the treatment workflow
Steps 5 and 6 above are part of a longer sequence. The complete order shows dose planning and evaluation as parts of the same process.
Tumor
The lesion being discussed as a target.
Imaging
CT, MRI, or PET-CT maps target location and size.
Target localization
The team defines the target boundary and structures to protect.
Dose planning
The plan defines dose, fractions, and beam angles.
Robotic irradiation
Radiation is delivered from many angles toward the target.
Tracking and correction
Target position is checked during the session and corrected if it shifts.
Evaluation
Follow-up imaging and response assessment are handled by the team.
When stereotactic therapy is discussed for lung cancer
Three situations most often serve as a starting point for discussion. Listing them here is not an assessment of an individual case or a list of indications for you.
Inoperable early-stage disease
In early-stage lung cancer, stereotactic therapy is discussed when surgery cannot be performed, for example because of the patient's general condition or the tumor's location. When surgery is feasible, it remains part of the treating team's discussion.
Oligometastatic context
When only a limited number of lesions are found, local treatment of those lesions may be discussed. Their number, size, and location are among the factors that change treatment considerations.
After previous treatment
Previous surgery, radiotherapy, and systemic treatment are considered, including the site, date, dose, and number of radiotherapy fractions if the same area was treated before.
What the doctor assesses
This list contains inputs for team assessment, not eligibility boxes for a patient to check independently.
Tumor location
How close it is to organs or tissue that must be protected.
Tumor size
Size affects whether focused irradiation can be planned.
Number of lesions
One lesion or several; the number changes the treatment consideration.
Prior radiotherapy
Site, date, dose, and fraction count if any.
Nearby critical organs
Structures that limit the maximum dose that can be delivered.
Motion and breathing
Moving targets change how tracking is used.
Functional status
General condition affects treatment choice.
Treatment goal
Local control, symptom relief, or another agreed goal.
What this list produces
Documents to send
These records have the greatest effect on the review. If one is not yet available, send what you have first; missing items can be added later.
Most recent CT / MRI / PET-CT
Include DICOM when available; this is often the most important file.
Radiology report
The official reading for the imaging above.
Pathology result
Tumor type and grade when a biopsy has been done.
Prior treatment summary
Surgery, radiotherapy, and systemic therapy with dates.
Prior radiotherapy history
Site, date, dose, fraction count, and plan if accessible.
Molecular / NGS result
When relevant for later options.
Functional status
If known and recorded by the treating team.
When it may not be suitable
This section does not assess an individual case or rule anyone out. It explains why a plan may be judged unsuitable so that your questions for the doctor can be more precise.
- Disease has spread widely so local therapy is no longer the main focus.
- Tumor size or location means focused dose cannot be delivered safely.
- Prior radiotherapy to the same area means cumulative dose limits must be calculated.
- The treatment goal is better answered by another approach, including systemic therapy or surgery.
- The patient's overall clinical condition makes focused therapy a lower priority.
Open frequently asked questions
Frequently asked questions
Short answers to the questions asked most often. The fuller explanation appears in the sections above.
Why are lung tumors hard to irradiate?
The target moves while the patient breathes, and its position may differ between sessions. That movement must be handled during planning.
How is radiation directed at a moving target?
The target position is checked during the session and irradiation is adjusted if the target shifts. This is a tracking and correction concept, not a guarantee that every target can be tracked.
Is stereotactic therapy for lung cancer only for patients who cannot have surgery?
Not always, but a common context is early-stage disease in patients who cannot undergo surgery, or limited-lesion situations. Final assessment remains with the team.
Does prior radiotherapy matter?
Yes. Previous dose, treatment field, and time since prior therapy must be known so cumulative dose limits can be assessed.
View facts and sources
Source separation
This page separates three things that are often mixed together: provider facts, facts from guidelines or scientific publications, and TanyaKanker explanations. Each line identifies its class so a provider claim is not read as independent evidence.
- PROVIDER
- According to Foshan CyberKnife Center materials
- EXTERNAL
- Guideline or scientific publication
- EXPLAINER
- TanyaKanker explanation
Installed technology
According to Foshan CyberKnife Center materialsCyberKnife M6 (Accuray platform)
Source: Foshan CyberKnife Center materials; consistent with the hospital's official website.
Provider
According to Foshan CyberKnife Center materialsFoshan Fosun Chancheng Hospital, Foshan, Guangdong, China
Source: Official hospital website (www.fsccyy.com).
Facility status
According to Foshan CyberKnife Center materialsPublic JCI-accredited national Grade III-A hospital, operating for almost 60 years
Source: Foshan CyberKnife Center materials.
Technical leadership
According to Foshan CyberKnife Center materialsLed by Dr. Jun Yang, medical physicist; contributor to CyberKnife quality-control standards TG-135 and TG-277
Source: Foshan CyberKnife Center materials.
Contact
According to Foshan CyberKnife Center materialsTel. +86 757 8216 2888 - Address: No.3 Sanyou South Road, Shiwanzhen, Chancheng, Foshan
Source: Foshan CyberKnife Center materials.
Technology origin
Guideline or scientific publicationCyberKnife was developed by Dr. John Adler, professor of neurosurgery at Stanford University; FDA cleared it for tumors in multiple body sites in 2001
Source: Public documentation and regulatory history.
Next step
Build a case summary from your reports so the target location, imaging, and previous treatment can be reviewed before you decide on the next care step.
This information is not a diagnosis or a medical recommendation. Decisions remain with your medical team.
Explore related pages
Related reading
- CyberKnife: what it is, who needs review, and the next stepA neutral explanation of CyberKnife: not surgery, not a replacement for surgery, and not suitable for every patient. Understand how it works, when it is discussed, and what a doctor must assess.
- CyberKnife vs SBRT: technique, platform, and a common misunderstandingSBRT is the technique; CyberKnife is one platform that can deliver it. A comparison of radiotherapy, SBRT, SRS, and CyberKnife without superiority claims.
- Lung Cancer: subtypes, biomarkers and treatment optionsLung Cancer: subtypes, biomarkers, diagnostics, treatment categories and related clinical trials. Review status and sources are shown on the page.
- SBRT (radioterapi stereotaktik): how it works, who it is for, what to prepareSBRT (radioterapi stereotaktik): how the treatment works, who is usually considered for it, what to prepare, and the biomarkers and clinical trials linked to it.
- Radioterapi: how it works, who it is for, what to prepareRadioterapi: how the treatment works, who is usually considered for it, what to prepare, and the biomarkers and clinical trials linked to it.
- Clinical trials: search by cancer, biomarker and countrySearch recruiting studies from the public ClinicalTrials.gov registry by cancer type, biomarker, treatment category, country and phase. Recruiting status is not a guarantee of eligibility.